Back to Search
Start Over
Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
- Source :
- GlobeNewswire. February 9, 2023
- Publication Year :
- 2023
-
Abstract
- The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.736330808